(Q24245109)

https://api.crossref.org/works/10.1002%2F14651858.CD003443.PUB2

A Double-Blind Trial of Amitriptyline/Perphenazine, Perphenazine and Placebo in Chronic Withdrawn Inert Schizophrenics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003443.PUB2

Loxapine versus perphenazine in psychotic patients. A double-blind, randomized, multicentre trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003443.PUB2

THE COMPARATIVE EFFECTIVENESS OF AMITRIPTYLINE, PERPHENAZINE, AND THEIR COMBINATION IN THE TREATMENT OF CHRONIC PSYCHOTIC FEMALE PATIENTS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003443.PUB2

Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003443.PUB2

Sulpiride and perphenazine in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003443.PUB2

Clozapine versus perphenazine: the value of the biochemical mode of action of neuroleptics in predicting their therapeutic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003443.PUB2

Zuclopenthixol and perphenazine in patients with acute psychotic states. A double-blind multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003443.PUB2

Evaluation of an amitriptyline-perphenazine combination in chronic schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003443.PUB2

Ritanserin as add-on medication to neuroleptic therapy for patients with chronic or subchronic schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003443.PUB2

Amitriptyline and perphenazine (Triptafen DA) in chronic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003443.PUB2

Metabolic interaction between amitriptyline and perphenazine in psychiatric patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003443.PUB2

Antiparkinsonian agents and long-term neuroleptic treatment. Effect of G 31.406, orphenadrine, and placebo on parkinsonism, schizophrenic symptoms, depression and anxiety

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003443.PUB2

Plasma levels of perphenazine and its major metabolites during simultaneous treatment with anticholinergic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003443.PUB2

PERPHENAZINE (TRILAFON) METABOLISM IN PSYCHOTIC PATIENTS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003443.PUB2

A comparison of perphenazine, proketazine, nialamide and MO-482 in chronic schizophrenics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003443.PUB2

Effects of perphenazine enanthate injections on prolactin levels in plasma from schizophrenic women and men

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003443.PUB2

TIME-SERIES, FREQUENCY ANALYSIS, AND ELECTROGENESIS OF THE EEGs OF NORMALS AND PSYCHOTICS BEFORE AND AFTER DRUGS

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003443.PUB2

Obsessive and compulsive symptoms in schizophrenia: a randomized controlled trial with fluvoxamine and neuroleptics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003443.PUB2

Trials of perphenazine in the prevention of postoperative vomiting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003443.PUB2

The pharmacological treatment of delusional depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003443.PUB2

A comparative study of the longacting neuroleptics perphenazin-enanthate and fluspirilene (author's transl)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003443.PUB2

Treatment of schizophrenic reactions with phenothiazine derivatives. A comparative study of chlorpromazine, triflupromazine, mepazine, prochlorperazine, perphenazine, and phenobarbital

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003443.PUB2

Specific therapeutic actions of acetophenazine, perphenazine, and benzquinamide in newly admitted schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003443.PUB2

Improving the quality of reporting of randomized controlled trials. The CONSORT statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003443.PUB2

Statistics notes. Trials randomised in clusters

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003443.PUB2

The unit of analysis error in studies about physicians' patient care behavior

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003443.PUB2

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003443.PUB2

Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003443.PUB2

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003443.PUB2

The positive and negative syndrome scale (PANSS) for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003443.PUB2

Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003443.PUB2

The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003443.PUB2

Competing voice messages. Effects of message load and drugs on the ability of acute schizophrenics to attend

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003443.PUB2

7 January 2021

Drug therapy of depression. Amitriptyline, perphenazine, and their combination in different syndromes

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003443.PUB2

7 January 2021

Specific indications for different classes of phenothiazines

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003443.PUB2

7 January 2021

Amitriptyline-perphenazine interaction in ambulatory schizophrenic patients. A controled study of drug interaction

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003443.PUB2

7 January 2021

Serum prolactin level increase in normal subjects following administration of perphenazine oral dosage forms: possible application to bioavailability testing

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003443.PUB2

7 January 2021

The comparative effectiveness of eight phenothiazines

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003443.PUB2

7 January 2021

A long-term cross-over pharmacokinetic study comparing perphenazine decanoate and haloperidol decanoate in schizophrenic patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003443.PUB2

7 January 2021

Perphenazine decanoate and cis(z)-flupentixol decanoate in maintenance treatment of schizophrenic outpatients. Serum levels at the minimum effective dose

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003443.PUB2

7 January 2021

The relationship between perphenazine plasma levels and clinical response in acute schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003443.PUB2

7 January 2021

The differential prediction of response to two anti-psychotic drugs

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003443.PUB2

7 January 2021

Immediate effects of chlorpromazine and perphenazine following neuroleptic washout on word association of schizophrenic patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003443.PUB2

7 January 2021

Control of postoperative vomiting with perphenazine (trilafon): a double blind study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003443.PUB2

7 January 2021

Fluvoxamine augmentation of antipsychotics improves negative symptoms in psychotic chronic schizophrenic patients: a placebo-controlled study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003443.PUB2

7 January 2021

The comparative effectiveness of six phenothiazine compounds, phenobarbital and inert placebo in the treatment of acutely ill patients: global measures of severity of illness.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003443.PUB2

7 January 2021

Attention to competing voice messages by nonacute schizophrenic patients. Effects of message load, drugs, dosage levels and patient background

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003443.PUB2

7 January 2021

PERPHENAZIN (TRILAFON) IN THE PROPHYLAXIS OF NAUSEA AND VOMITING FOLLOWING ACUTE MYOCARDIAL INFARCT

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003443.PUB2

7 January 2021

A double blind controlled trial of thiothixene and perphenazine in chronic schizophrenics shown to require maintenance therapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003443.PUB2

7 January 2021

Clinical experience with depot neuroleptics

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003443.PUB2

7 January 2021

Poor neuroleptic response in acutely exacerbated schizophrenic patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003443.PUB2

7 January 2021

Perphenazine-a drug modifying consciousness

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003443.PUB2

7 January 2021

Trilafon in the treatment of chronically psychotic hospitalized patients.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003443.PUB2

7 January 2021

Therapeutic implications of differential effects of new phenothiazine compounds

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003443.PUB2

7 January 2021

A graphic comparison of five phenothiazines

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003443.PUB2

7 January 2021

Thresholds for drug-induced akathisia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003443.PUB2

7 January 2021

CLINICAL TRIAL OF A POTENTIATED DIKETOPIPERAZINE DERIVATIVE AS A PSYCHOPHARMACOLOGICAL AGENT FOR THE TREATMENT OF PSYCHOTIC PATIENTS

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003443.PUB2

7 January 2021

Perphenazine-Amitriptyline in the Treatment of Schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003443.PUB2

7 January 2021

Interaction between antidepressants and perphenazine in psychiatric inpatients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003443.PUB2

7 January 2021

Comparison of Efficacy of a New Butyrophenone Derivative, Timiperone and Perphenazine in Schizophrenia by a Multicentre Controlled Study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003443.PUB2

7 January 2021

Citalopram causes no significant alterations in plasma neuroleptic levels in schizophrenic patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003443.PUB2

7 January 2021

Relationship of adverse drug reactions to length of hospital-stay in genetically subgrouped schizophrenics

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003443.PUB2

7 January 2021

Withdrawal of perphenazine in chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003443.PUB2

7 January 2021

Penicillamine and Schizophrenia—A Clinical Trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003443.PUB2

7 January 2021